Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast

Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024


Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets on Thursday, May 9, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results.

To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=7144015a&confId=62782

After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Thursday, May 23, 2024 at US: 1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 952508

To join the webcast, please visit "Events" on investor relations page of the Company's website at www.xerispharma.com or use this link: https://events.q4inc.com/attendee/702822810

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, for a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing's syndrome. Xeris also has a pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSoltm and XeriJect®, supporting long-term product development and commercial success.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.


These press releases may also interest you

at 20:10
/DISREGARD RELEASE: Hidden River Eating Disorder Residential Treatment/
We are advised by Hidden River Eating Disorder Residential Treatment that journalists and other readers should disregard the news release, Hidden River Announces Insurance Contract with Blue Cross Blue Shield, issued 16-May-2024 over PR Newswire....

at 20:00
Full-Life Technologies Announces Appointment of Mark S. de Jong, PhD, as Chief Technical Officer
Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the appointment of Mark S. de Jong, PhD, to the newly created position of Chief Technical Officer (CTO). Dr. de Jong, joins Full-Life with 43...

at 19:20
Whitman-Walker Institute Decries Misleading Propaganda About Transgender Health During Congressional Hearing
Whitman-Walker Institute, which leverages research, policy, and education to advance health equity nationwide, says it's standing by to further inform the chair of the U.S. House Committee on Education and the Workforce and others about the strong...

at 18:50
AKRO Investors: Reminder - Important Deadline in Securities Fraud Class Action Lawsuit Akero Therapeutics, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc....

at 18:46
FDA APPROVES IMDELLTRAtm (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRAtm (tarlatamab-dlle) for the...

at 18:42
Join Housecall Providers at Toss for a Cause: A Free, Community-wide Event Spotlighting Nonprofit Innovation in Elder and Disability Care
Housecall Providers, a nonprofit home-based medical organization invites the community to Sellwood Park, Saturday, June 1, from noon ? 4:00 p.m. for an inspiring afternoon of learning, connection and some friendly competition. Toss...

More news about Health...


News published on and distributed by: